Palliative treatment with carboplatin as late line therapy to patients with metastatic breast cancer

References

• Perez EA. Carboplatin in combination therapy for metastatic breast cancer. Oncologist. 2004;9:518–527.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol. 2014;25:1871–1888.
   PubMed Web of Science ®Google Scholar
• Bang SM, Park SH, Kang HG, et al. Changes in quality of life during palliative chemotherapy for solid cancer. Support Care Cancer. 2005;13:515–521.
   PubMed Web of Science ®Google Scholar
• Park YH, Jung KH, Im SA, et al. Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02). Breast Cancer Res Treat. 2015;152:77–85.
   PubMed Web of Science ®Google Scholar
• Matsuyama R, Reddy S, Smith TJ. Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol. 2006;24:3490–3496.
   PubMed Web of Science ®Google Scholar
• Balmer CE, Thomas P, Osborne RJ. Who wants second-line, palliative chemotherapy? Psychooncology. 2001;10:410–418.
   PubMed Web of Science ®Google Scholar
• de Haes H, Koedoot N. Patient centered decision making in palliative cancer treatment: a world of paradoxes. Patient Educ Couns. 2003;50:43–49.
   PubMed Web of Science ®Google Scholar
• Martin M, Diaz-Rubio E, Casado A, et al. Carboplatin: an active drug in metastatic breast cancer. J Clin Oncol. 1992;10:433–437.
   PubMed Web of Science ®Google Scholar
• Kolaric K, Vukas D. Carboplatin activity in untreated metastatic breast cancer patients-results of a phase II study. Cancer Chemother Pharmacol. 1991;27:409–412.
   PubMed Web of Science ®Google Scholar
• Liu J, Li Q, Zhang P, et al. Paclitaxel plus carboplatin for women with advanced breast cancer. Chin Med Sci J. 2007;22:93–97.
   PubMedGoogle Scholar
• Ruiz M, Salvador J, Bayo J, et al. Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer. Cancer Chemother Pharmacol. 2008;62:1085–1090.
   PubMed Web of Science ®Google Scholar
• Yardley DA, Burris HA, III Simons L, et al. A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer. Clin Breast Cancer. 2008;8:425–431.
   PubMed Web of Science ®Google Scholar
• Loesch D, Asmar L, McIntyre K, et al. Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer. Clin Breast Cancer. 2008;8:178–186.
   PubMed Web of Science ®Google Scholar
• Maisano R, Zavettieri M, Azzarello D, et al. Carboplatin and gemcitabine combination in metastatic triple-negative anthracycline- and taxane- pretreated breast cancer patients: a phase II study. Cancer. 2011;23:40–43.
   Google Scholar
• O'Brien ME, Talbot DC, Smith IE. Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule. J Clin Oncol. 1993;11:2112–2117.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Gundersen S, Clavel M, et al. Randomized phase II trial of iproplatin and carboplatin in advanced breast cancer. The EORTC Early Clinical Trials Group and the EORTC Data Center. Ann Oncol. 1993;4:303–306.
   PubMed Web of Science ®Google Scholar
• Chan D, Yeo WL, Tiemsim Cordero M, et al. Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes. Invest New Drugs. 2010;28:859–865.
   PubMed Web of Science ®Google Scholar
• Nasr FL, Chahine GY, Kattan JG, et al. Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer. Clin Breast Cancer. 2004;5:117–122. discussion 123–4.
   PubMedGoogle Scholar
• Nagourney RA, Flam M, Link J, et al. Carboplatin plus gemcitabine repeating doublet therapy in recurrent breast cancer. Clin Breast Cancer. 2008;8:432–435.
   PubMed Web of Science ®Google Scholar
• Nelli F, Moscetti L, Natoli G, et al. Gemcitabine and carboplatin for pretreated metastatic breast cancer: the predictive value of immunohistochemically defined subtypes. Int J Clin Oncol. 2013;18:343–349.
   PubMed Web of Science ®Google Scholar
• Laessig D, Stemmler HJ, Vehling-Kaiser U, et al. Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer. Oncology. 2007;73:407–414.
   PubMed Web of Science ®Google Scholar
• Koshy N, Quispe D, Shi R, et al. Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast. 2010;19:246–248.
   PubMed Web of Science ®Google Scholar
• Isakoff SJ, Mayer EL, He L, et al. TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol. 2015;33:1902–1909.
   PubMed Web of Science ®Google Scholar
• Goncalves JF, Goyanes C. Use of chemotherapy at the end of life in a Portuguese oncology center. Support Care Cancer. 2008; 16:321–327.
   PubMed Web of Science ®Google Scholar